Management say recruitment is on track and I will take them at their word. I believe the extension of the trial into Victoria is prompted by compassionate considerations and has nothing to do with any need to boost numbers. It's unfortunate it didn't happen sooner. As to the suggestion that there are insufficent takers in the US, what therapy do you think people who are stuck on ventilators (or their families) would opt for ahead of remestemsel (or the chance of being randomised to remestemcel) if given the choice? Remdesivir? Convalescent plasma? Look at the trial results for both of these and you will see that they offer the critical cases very little hope. Sure there are a few other experimental treatments about (mostly mAbs and JAK inhibitors) but these are mostly in phase 1 or 2 or are not being offered to paitents with ARDS classified as critical.
Ann: Ethics Approval to Treat COVID-19 Patients in Australia, page-168
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |